\-\ Texto\\:\\ \ \(0\)\
\-\ general\\:\\ \\ well\\-nourished\\,\\ well\\-appearing\\,\\ no\\ acute\\ distress\\.\\ \ \(0\)\
\-\ musculoskeletal\\:\\ \\ point\\ tenderness\\ over\\ lateral\\ aspect\\ of\\ knee\\,\\ slightly\\ below\\ the\\ joint\\ line\\.\\ \\ approximately\\ a\\ 2\\ cm\\ hard\\ nodule\\ felt\\ on\\ palpation\\.\\ \\ nodule\\ is\\ non\\-mobile\\.\\ \\ no\\ erythema\\,\\ swelling\\,\\ tenderness\\.\ \(0\)\
\-\ laboratory\\:\\ \\ unremarkable\ \(0\)\
\-\ patient\\ was\\ referred\\ to\\ outpatient\\ management\\ for\\ further\\ workup\\ of\\ the\\ lytic\\ lesion\\ and\\ excisional\\ removal\\ with\\ wide\\ margins\\.\ \(0\)\
\-\ anteroposterior\\,\\ lateral\\ and\\ tunnel\\ radiographs\\ of\\ the\\ right\\ knee\\ show\\ an\\ expansile\\ lytic\\ lesion\\ of\\ the\\ proximal\\ fibula\\ with\\ fairly\\ narrow\\ zone\\ of\\ transition\\.\\ \\ lesion\\ measures\\ approximately\\ 4\\.0\\ x\\ 3\\.9\\ cm\\ ap\\ x\\ lr\\ and\\ extends\\ approximately\\ 7\\.0\\ cm\\ si\\.\\ \\ \ \(0\)\
\-\ on\\ bone\\ scans\\,\\ mass\\ demonstrates\\ \\ that\\ increased\\ radiotracer\\ accumulation\\,\\ with\\ suggestion\\ of\\ a\\ mild\\ photopenic\\ area\\ centrally\\.\\ \\ tibia\\ and\\ femur\\ are\\ otherwise\\ normal\\ in\\ appearance\\.\\ no\\ additional\\ abnormal\\ radiotracer\\ uptake\\ throughout\\ the\\ remainder\\ of\\ the\\ regions\\ of\\ the\\ left\\ and\\ right\\ knees\\.\\ no\\ associated\\ periosteal\\ reaction\\ or\\ soft\\ tissue\\ mass\\.\\ \\ \\ normal\\ soft\\ tissue\\ radiolabel\\ uptake\\.\ \(0\)\
\-\ giant\\ cell\\ bone\\ tumor\ \(0\)\
\-\ giant\\ cell\\ bone\\ tumor\ \(0\)\
\-\ aneurysmal\\ bone\\ cyst\ \(11\)\
\-\ brown\\ tumors\\ of\\ hyperparathyroidism\ \(0\)\
\-\ malignant\\ fibrous\\ histiocytomas\ \(2\)\
\-\ chondroblastomas\ \(2\)\
\-\ lytic\\ metastasis\ \(2\)\
\-\ telangiectatic\\ osteosarcoma\ \(2\)\
\-\ 21\\ year\\ old\\ woman\\,\\ complaining\\ about\\ pain\\ in\\ her\\ right\\ knee\\ for\\ the\\ past\\ 4\\ months\\.\\ \\ pain\\ has\\ gradually\\ increased\\ in\\ intensity\\,\\ interfering\\ with\\ her\\ fitness\\ routine\\.\\ \\ \\ pain\\ is\\ not\\ worse\\ during\\ the\\ mornings\\ or\\ at\\ night\\.\\ \\ no\\ fevers\\,\\ chills\\ nor\\ night\\ sweats\\.\ \(0\)\
\-\ giant\\ cell\\ bone\\ tumors\\ are\\ destructive\\ lesions\\ of\\ bone\\ that\\ may\\ be\\ well\\-defined\\ althoughs\\ sometimes\\ aggressive\\.\\ \\ \\ giant\\ cells\\ are\\ large\\ cells\\ which\\ consist\\ of\\ fused\\ stromal\\ cells\\.\\ \\ these\\ tumors\\ are\\ very\\ rare\\,\\ affecting\\ approximately\\ one\\ a\\ million\\,\\ usually\\ between\\ the\\ ages\\ of\\ 25\\ and\\ 40\\,\\ with\\ most\\ tumors\\ occurring\\ in\\ the\\ 30\\â\\€\\™s\\.\\ \\ women\\ are\\ affected\\ slightly\\ more\\ than\\ men\\ \\(50\\-57\\%\\)\\.\\ \\ \\ this\\ syndrome\\ does\\ not\\ have\\ a\\ genetic\\ link\\,\\ nor\\ a\\ known\\ cause\\.\ \(0\)\
\-\ reference\\:\ \(0\)\
\-\ resnick\\ d\\.\\ tumors\\ and\\ tumor\\-like\\ lesion\\ of\\ bone\\:\\ imaging\\ and\\ pathology\\ of\\ specific\\ lesions\\.\\ in\\ resnick\\ d\\,\\ ed\\.\\ we\\.\\ saunders\\ co\\.\\ vol\\ 6\\ 1995\\;\\ pp3787\\-3806\ \(0\)\
\-\ giant\\ cell\\ tumors\\ are\\ seen\\ on\\ radiographs\\ as\\ expansive\\ osteolytic\\ lesions\\ surrounded\\ by\\ a\\ thin\\ rim\\ of\\ white\\ bone\\.\\ \\ they\\ are\\ usually\\ near\\ a\\ joint\\,\\ with\\ 60\\%\\ occurring\\ at\\ the\\ epimetaphyseal\\ region\\ of\\ long\\ bones\\.\\ \\ fifty\\ percent\\ occur\\ around\\ the\\ knee\\ joint\\.\\ \\ they\\ are\\ almost\\ exclusively\\ seen\\ when\\ the\\ epiphysis\\ of\\ the\\ bone\\ is\\ closed\\.\\ \\ in\\ 5\\-10\\%\\,\\ these\\ tumors\\ may\\ metastasize\\ to\\ the\\ lungs\\.\ \(0\)\
\-\ giant\\ cell\\ tumors\\ present\\ with\\ progressive\\ pain\\ as\\ the\\ bone\\ tumor\\ irritates\\ the\\ periosteum\\ and\\ sometimes\\ leads\\ to\\ a\\ pathologic\\ fracture\\.\\ \ \(0\)\
\-\ treatment\\ is\\ surgical\\ \\â\\€\\“\\ intralesional\\ excision\\ with\\ extensive\\ curettage\\ or\\ may\\ be\\ resection\\ depending\\ upon\\ the\\ extension\\ outside\\ the\\ bone\\ and\\ into\\ the\\ joint\\.\\ \\ various\\ methods\\ are\\ available\\ to\\ ensure\\ tumor\\ cell\\ destruction\\.\\ \\ the\\ lytic\\ lesion\\ is\\ stabilized\\ with\\ cement\\ or\\ bone\\ graft\\.\\ \\ non\\-weight\\ bearing\\ bones\\ may\\ be\\ simply\\ removed\\ with\\ wide\\ excision\\.\\ \\ patients\\ with\\ lung\\ metastases\\ should\\ be\\ further\\ evaluated\\ for\\ resection\\ of\\ metastases\\(which\\,\\ surprisingly\\,\\ may\\ not\\ be\\ necessary\\)\\.\ \(0\)\
\-\ prognosis\\ is\\ good\\,\\ even\\ with\\ metastatic\\ disease\\.\\ \\ local\\ recurrence\\ rates\\ are\\ high\\,\\ with\\ a\\ 10\\%\\ to\\ 50\\%\\ recurrence\\ rate\\.\\ \\ patients\\ should\\ be\\ periodically\\ followed\\ for\\ 2\\ years\\ after\\ excision\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ bone\\:\\ 0\\.28751785686078235\ \(0\)\
\-\ tumors\\:\\ 0\\.2583608305543805\ \(0\)\
\-\ giant\\:\\ 0\\.23501704115760855\ \(0\)\
\-\ the\\:\\ 0\\.19276530043220735\ \(0\)\
\-\ are\\:\\ 0\\.16662652484582371\ \(0\)\
\-\ of\\:\\ 0\\.15468133587388608\ \(0\)\
\-\ cell\\:\\ 0\\.1507185351816271\ \(0\)\
\-\ lytic\\:\\ 0\\.14795628563421415\ \(0\)\
\-\ knee\\:\\ 0\\.1259027083240269\ \(0\)\
\-\ joint\\:\\ 0\\.11574332767336674\ \(0\)\
\-\ tumor\\:\\ 0\\.11484293298107226\ \(0\)\
\-\ approximately\\:\\ 0\\.11207652210598487\ \(0\)\
\-\ with\\:\\ 0\\.11178104739765325\ \(0\)\
\-\ may\\:\\ 0\\.1104898174929537\ \(0\)\
\-\ be\\:\\ 0\\.10688034979680915\ \(0\)\
\-\ resnick\\:\\ 0\\.10662166610802896\ \(0\)\
\-\ lesion\\:\\ 0\\.10526223625777353\ \(0\)\
\-\ excision\\:\\ 0\\.10386617434091104\ \(0\)\
\-\ cells\\:\\ 0\\.10150100612623993\ \(0\)\
\-\ and\\:\\ 0\\.09073902014341198\ \(0\)\
\-\ occurring\\:\\ 0\\.0886072789642592\ \(0\)\
\-\ nor\\:\\ 0\\.08549364532910236\ \(0\)\
\-\ wide\\:\\ 0\\.08506595186908739\ \(0\)\
\-\ sometimes\\:\\ 0\\.08218879259870203\ \(0\)\
\-\ night\\:\\ 0\\.07889388366150304\ \(0\)\
\-\ radiotracer\\:\\ 0\\.07666248311581915\ \(0\)\
\-\ cm\\:\\ 0\\.0756576861802743\ \(0\)\
\-\ lesions\\:\\ 0\\.0756576861802743\ \(0\)\
\-\ recurrence\\:\\ 0\\.07251074972130335\ \(0\)\
\-\ is\\:\\ 0\\.07215379464969612\ \(0\)\
\-\ no\\:\\ 0\\.07139860903949592\ \(0\)\
\-\ metastases\\:\\ 0\\.07100100178591662\ \(0\)\
\-\ bones\\:\\ 0\\.0706662935065007\ \(0\)\
\-\ althoughs\\:\\ 0\\.07022503981205877\ \(0\)\
\-\ nodule\\:\\ 0\\.06931977227375895\ \(0\)\
\-\ slightly\\:\\ 0\\.06850732614658307\ \(0\)\
\-\ uptake\\:\\ 0\\.06753168918776777\ \(0\)\
\-\ radiolabel\\:\\ 0\\.06710377458389141\ \(0\)\
\-\ mornings\\:\\ 0\\.06710377458389141\ \(0\)\
\-\ epimetaphyseal\\:\\ 0\\.06710377458389141\ \(0\)\
\-\ irritates\\:\\ 0\\.06710377458389141\ \(0\)\
\-\ in\\:\\ 0\\.06554346218214044\ \(0\)\
\-\ histiocytomas\\:\\ 0\\.06488920166120399\ \(0\)\
\-\ chondroblastomas\\:\\ 0\\.06488920166120399\ \(0\)\
\-\ interfering\\:\\ 0\\.06488920166120399\ \(0\)\
\-\ expansive\\:\\ 0\\.06488920166120399\ \(0\)\
\-\ surprisingly\\:\\ 0\\.063171445450672\ \(0\)\
\-\ pain\\:\\ 0\\.06285349044971562\ \(0\)\
\-\ they\\:\\ 0\\.06275205073833513\ \(0\)\
\-\ fitness\\:\\ 0\\.06176793643303663\ \(0\)\
\-\ million\\:\\ 0\\.06176793643303663\ \(0\)\
\-\ 50\\:\\ 0\\.06133424214425815\ \(0\)\
\-\ or\\:\\ 0\\.061104978733336424\ \(0\)\
\-\ lr\\:\\ 0\\.05955336351034921\ \(0\)\
\-\ telangiectatic\\:\\ 0\\.05955336351034921\ \(0\)\
\-\ fifty\\:\\ 0\\.05955336351034921\ \(0\)\
\-\ cement\\:\\ 0\\.058646671204869265\ \(0\)\
\-\ periodically\\:\\ 0\\.058646671204869265\ \(0\)\
\-\ should\\:\\ 0\\.05730531126356595\ \(0\)\
\-\ further\\:\\ 0\\.05720140103012955\ \(0\)\
\-\ radiographs\\:\\ 0\\.05696163684894521\ \(0\)\
\-\ resection\\:\\ 0\\.056296480514274494\ \(0\)\
\-\ intralesional\\:\\ 0\\.055815930539918\ \(0\)\
\-\ usually\\:\\ 0\\.05528861320909121\ \(0\)\
\-\ tenderness\\:\\ 0\\.05507666921044106\ \(0\)\
\-\ to\\:\\ 0\\.05488971890120156\ \(0\)\
\-\ her\\:\\ 0\\.05486760329889104\ \(0\)\
\-\ metastasize\\:\\ 0\\.05375083779436871\ \(0\)\
\-\ simply\\:\\ 0\\.05375083779436871\ \(0\)\
\-\ photopenic\\:\\ 0\\.05331083305401448\ \(0\)\
\-\ stabilized\\:\\ 0\\.05331083305401448\ \(0\)\
\-\ for\\:\\ 0\\.053237706420829575\ \(0\)\
\-\ methods\\:\\ 0\\.05249976914896244\ \(0\)\
\-\ excisional\\:\\ 0\\.0521241830877865\ \(0\)\
\-\ tunnel\\:\\ 0\\.0521241830877865\ \(0\)\
\-\ exclusively\\:\\ 0\\.0521241830877865\ \(0\)\
\-\ not\\:\\ 0\\.052006381423169094\ \(0\)\
\-\ si\\:\\ 0\\.05176607260106057\ \(0\)\
\-\ periosteum\\:\\ 0\\.05176607260106057\ \(0\)\
\-\ vol\\:\\ 0\\.05142388350002927\ \(0\)\
\-\ osteolytic\\:\\ 0\\.05142388350002927\ \(0\)\
\-\ 10\\:\\ 0\\.051355155231194355\ \(0\)\
\-\ anteroposterior\\:\\ 0\\.051096260131327065\ \(0\)\
\-\ co\\:\\ 0\\.051096260131327065\ \(0\)\
\-\ consist\\:\\ 0\\.04990961016509908\ \(0\)\
\-\ these\\:\\ 0\\.04959433459918121\ \(0\)\
\-\ patients\\:\\ 0\\.04940593827108132\ \(0\)\
\-\ brown\\:\\ 0\\.04841499964351394\ \(0\)\
\-\ curettage\\:\\ 0\\.04841499964351394\ \(0\)\
\-\ stromal\\:\\ 0\\.04797499490315971\ \(0\)\
\-\ saunders\\:\\ 0\\.04797499490315971\ \(0\)\
\-\ increased\\:\\ 0\\.047491173036829\ \(0\)\
\-\ suggestion\\:\\ 0\\.04735882716089586\ \(0\)\
\-\ link\\:\\ 0\\.04735882716089586\ \(0\)\
\-\ 1995\\:\\ 0\\.04735882716089586\ \(0\)\
\-\ destructive\\:\\ 0\\.046788344936931715\ \(0\)\
\-\ soft\\:\\ 0\\.04675575664617294\ \(0\)\
\-\ fused\\:\\ 0\\.04660720746813544\ \(0\)\
\-\ fairly\\:\\ 0\\.04608804534917449\ \(0\)\
\-\ tissue\\:\\ 0\\.046070616926886056\ \(0\)\
\-\ transition\\:\\ 0\\.04592249085581936\ \(0\)\
\-\ knees\\:\\ 0\\.04576042198047228\ \(0\)\
\-\ gradually\\:\\ 0\\.04576042198047228\ \(0\)\
\-\ ensure\\:\\ 0\\.04576042198047228\ \(0\)\
\-\ graft\\:\\ 0\\.04576042198047228\ \(0\)\
\-\ rates\\:\\ 0\\.04576042198047228\ \(0\)\
\-\ surrounded\\:\\ 0\\.04514425423820844\ \(0\)\
\-\ outpatient\\:\\ 0\\.04499762147639377\ \(0\)\
\-\ fibula\\:\\ 0\\.04499762147639377\ \(0\)\
\-\ sweats\\:\\ 0\\.04485372967499235\ \(0\)\
\-\ ages\\:\\ 0\\.04485372967499235\ \(0\)\
\-\ men\\:\\ 0\\.04471247823967381\ \(0\)\
\-\ leads\\:\\ 0\\.0443036394821296\ \(0\)\
\-\ affecting\\:\\ 0\\.04417204675226794\ \(0\)\
\-\ various\\:\\ 0\\.0439154234144466\ \(0\)\
\-\ right\\:\\ 0\\.04367605418872821\ \(0\)\
\-\ lateral\\:\\ 0\\.043585241722082474\ \(0\)\
\-\ hard\\:\\ 0\\.04342649802767645\ \(0\)\
\-\ percent\\:\\ 0\\.04342649802767645\ \(0\)\
\-\ epiphysis\\:\\ 0\\.04342649802767645\ \(0\)\
\-\ centrally\\:\\ 0\\.04330896922203843\ \(0\)\
\-\ genetic\\:\\ 0\\.04330896922203843\ \(0\)\
\-\ bearing\\:\\ 0\\.04319320783398118\ \(0\)\
\-\ narrow\\:\\ 0\\.043079161492659154\ \(0\)\
\-\ aneurysmal\\:\\ 0\\.043079161492659154\ \(0\)\
\-\ reference\\:\\ 0\\.042966780121007124\ \(0\)\
\-\ closed\\:\\ 0\\.04263915675230493\ \(0\)\
\-\ zone\\:\\ 0\\.04242823979863698\ \(0\)\
\-\ accumulation\\:\\ 0\\.04242823979863698\ \(0\)\
\-\ we\\:\\ 0\\.04222294797290603\ \(0\)\
\-\ hyperparathyroidism\\:\\ 0\\.04182809284725288\ \(0\)\
\-\ depending\\:\\ 0\\.04182809284725288\ \(0\)\
\-\ musculoskeletal\\:\\ 0\\.0416380094306291\ \(0\)\
\-\ osteosarcoma\\:\\ 0\\.04154469935192907\ \(0\)\
\-\ workup\\:\\ 0\\.041361405282127166\ \(0\)\
\-\ seen\\:\\ 0\\.041346941235108924\ \(0\)\
\-\ destruction\\:\\ 0\\.04003373911678715\ \(0\)\
\-\ chills\\:\\ 0\\.03995789626449179\ \(0\)\
\-\ which\\:\\ 0\\.039934555872139954\ \(0\)\
\-\ on\\:\\ 0\\.03978664207193875\ \(0\)\
\-\ erythema\\:\\ 0\\.03973475057554495\ \(0\)\
\-\ expansile\\:\\ 0\\.03973475057554495\ \(0\)\
\-\ complaining\\:\\ 0\\.03973475057554495\ \(0\)\
\-\ women\\:\\ 0\\.039517891524137566\ \(0\)\
\-\ almost\\:\\ 0\\.03944694183075152\ \(0\)\
\-\ fevers\\:\\ 0\\.038771246298263805\ \(0\)\
\-\ remainder\\:\\ 0\\.038642943540917164\ \(0\)\
\-\ periosteal\\:\\ 0\\.038642943540917164\ \(0\)\
\-\ prognosis\\:\\ 0\\.038642943540917164\ \(0\)\
\-\ felt\\:\\ 0\\.03857958526359182\ \(0\)\
\-\ scans\\:\\ 0\\.038210010906930096\ \(0\)\
\-\ that\\:\\ 0\\.03811242674219379\ \(0\)\
\-\ aggressive\\:\\ 0\\.03797313107118365\ \(0\)\
\-\ local\\:\\ 0\\.03780013531360558\ \(0\)\
\-\ regions\\:\\ 0\\.03768692757866155\ \(0\)\
\-\ tibia\\:\\ 0\\.037520177652857534\ \(0\)\
\-\ evaluated\\:\\ 0\\.037520177652857534\ \(0\)\
\-\ margins\\:\\ 0\\.03746538747679723\ \(0\)\
\-\ reaction\\:\\ 0\\.03735696332891981\ \(0\)\
\-\ removed\\:\\ 0\\.03730331860145015\ \(0\)\
\-\ even\\:\\ 0\\.03693792180349475\ \(0\)\
\-\ worse\\:\\ 0\\.036786481104955665\ \(0\)\
\-\ necessary\\:\\ 0\\.03673665577088573\ \(0\)\
\-\ point\\:\\ 0\\.036302171279774316\ \(0\)\
\-\ below\\:\\ 0\\.036162626904500304\ \(0\)\
\-\ extends\\:\\ 0\\.036162626904500304\ \(0\)\
\-\ affected\\:\\ 0\\.03611666863522216\ \(0\)\
\-\ femur\\:\\ 0\\.03602556713127239\ \(0\)\
\-\ pathologic\\:\\ 0\\.0359804175165713\ \(0\)\
\-\ normal\\:\\ 0\\.03585804842671043\ \(0\)\
\-\ measures\\:\\ 0\\.035802421442325545\ \(0\)\
\-\ near\\:\\ 0\\.03575855814849623\ \(0\)\
\-\ good\\:\\ 0\\.035714943373245794\ \(0\)\
\-\ distress\\:\\ 0\\.03537464543725022\ \(0\)\
\-\ as\\:\\ 0\\.035282114242012476\ \(0\)\
\-\ general\\:\\ 0\\.03525081455410981\ \(0\)\
\-\ outside\\:\\ 0\\.03525081455410981\ \(0\)\
\-\ ed\\:\\ 0\\.035128944136893575\ \(0\)\
\-\ 21\\:\\ 0\\.035088745678762724\ \(0\)\
\-\ around\\:\\ 0\\.03504875604473267\ \(0\)\
\-\ rim\\:\\ 0\\.03496939464865431\ \(0\)\
\-\ upon\\:\\ 0\\.03454695520340395\ \(0\)\
\-\ pathology\\:\\ 0\\.034472577936498876\ \(0\)\
\-\ line\\:\\ 0\\.03421777495589389\ \(0\)\
\-\ thin\\:\\ 0\\.034182053373282784\ \(0\)\
\-\ fibrous\\:\\ 0\\.03411110367989675\ \(0\)\
\-\ additional\\:\\ 0\\.03404080193796425\ \(0\)\
\-\ routine\\:\\ 0\\.034005890371373165\ \(0\)\
\-\ extensive\\:\\ 0\\.03383366870874664\ \(0\)\
\-\ progressive\\:\\ 0\\.03363196318042005\ \(0\)\
\-\ removal\\:\\ 0\\.033565885631018935\ \(0\)\
\-\ mass\\:\\ 0\\.03354651530452698\ \(0\)\
\-\ specific\\:\\ 0\\.03327536106780284\ \(0\)\
\-\ rate\\:\\ 0\\.03327536106780284\ \(0\)\
\-\ at\\:\\ 0\\.03317232738502819\ \(0\)\
\-\ rare\\:\\ 0\\.033149676851620034\ \(0\)\
\-\ about\\:\\ 0\\.032874172756075314\ \(0\)\
\-\ 60\\:\\ 0\\.032844161071905256\ \(0\)\
\-\ referred\\:\\ 0\\.032492861155595465\ \(0\)\
\-\ management\\:\\ 0\\.03243583876716317\ \(0\)\
\-\ lungs\\:\\ 0\\.032407485190949596\ \(0\)\
\-\ throughout\\:\\ 0\\.032295103819297566\ \(0\)\
\-\ 40\\:\\ 0\\.032295103819297566\ \(0\)\
\-\ occur\\:\\ 0\\.032295103819297566\ \(0\)\
\-\ metastasis\\:\\ 0\\.03218433950200275\ \(0\)\
\-\ laboratory\\:\\ 0\\.03188770784823293\ \(0\)\
\-\ ap\\:\\ 0\\.03152599090220505\ \(0\)\
\-\ very\\:\\ 0\\.03150079288546965\ \(0\)\
\-\ otherwise\\:\\ 0\\.031302124124105955\ \(0\)\
\-\ malignant\\:\\ 0\\.031302124124105955\ \(0\)\
\-\ intensity\\:\\ 0\\.03118051042198619\ \(0\)\
\-\ 25\\:\\ 0\\.031108453853069578\ \(0\)\
\-\ extension\\:\\ 0\\.03108458410607075\ \(0\)\
\-\ does\\:\\ 0\\.030357390152309635\ \(0\)\
\-\ 30\\:\\ 0\\.02995603243251574\ \(0\)\
\-\ cause\\:\\ 0\\.02991497640325503\ \(0\)\
\-\ available\\:\\ 0\\.029793105986038796\ \(0\)\
\-\ followed\\:\\ 0\\.029653320275636958\ \(0\)\
\-\ palpation\\:\\ 0\\.02961384333148443\ \(0\)\
\-\ swelling\\:\\ 0\\.029555004926011347\ \(0\)\
\-\ unremarkable\\:\\ 0\\.02943866033501134\ \(0\)\
\-\ long\\:\\ 0\\.029118257214366262\ \(0\)\
\-\ white\\:\\ 0\\.028971972769885623\ \(0\)\
\-\ past\\:\\ 0\\.02858345977495955\ \(0\)\
\-\ between\\:\\ 0\\.028531968029531393\ \(0\)\
\-\ area\\:\\ 0\\.028446906531571545\ \(0\)\
\-\ known\\:\\ 0\\.028430006443029104\ \(0\)\
\-\ aspect\\:\\ 0\\.028329377725933524\ \(0\)\
\-\ show\\:\\ 0\\.0278764243076074\ \(0\)\
\-\ during\\:\\ 0\\.02781383870076526\ \(0\)\
\-\ proximal\\:\\ 0\\.02743380164944552\ \(0\)\
\-\ years\\:\\ 0\\.026917542058228078\ \(0\)\
\-\ lung\\:\\ 0\\.02671225023249712\ \(0\)\
\-\ when\\:\\ 0\\.026525461481979356\ \(0\)\
\-\ appearance\\:\\ 0\\.026472915289972025\ \(0\)\
\-\ syndrome\\:\\ 0\\.026472915289972025\ \(0\)\
\-\ abnormal\\:\\ 0\\.026381813786022258\ \(0\)\
\-\ region\\:\\ 0\\.026266245501785187\ \(0\)\
\-\ months\\:\\ 0\\.025560406597937152\ \(0\)\
\-\ cyst\\:\\ 0\\.0253312829212743\ \(0\)\
\-\ one\\:\\ 0\\.025141750127821532\ \(0\)\
\-\ fracture\\:\\ 0\\.02495677192290845\ \(0\)\
\-\ high\\:\\ 0\\.02495677192290845\ \(0\)\
\-\ mild\\:\\ 0\\.02489253243546284\ \(0\)\
\-\ than\\:\\ 0\\.02489253243546284\ \(0\)\
\-\ over\\:\\ 0\\.02441706937705317\ \(0\)\
\-\ more\\:\\ 0\\.024112450687274533\ \(0\)\
\-\ metastatic\\:\\ 0\\.024083601232249965\ \(0\)\
\-\ acute\\:\\ 0\\.023754778146060845\ \(0\)\
\-\ into\\:\\ 0\\.023342927129155464\ \(0\)\
\-\ associated\\:\\ 0\\.023144980273617825\ \(0\)\
\-\ imaging\\:\\ 0\\.023077305224665997\ \(0\)\
\-\ woman\\:\\ 0\\.022869575749123194\ \(0\)\
\-\ most\\:\\ 0\\.02285319704669074\ \(0\)\
\-\ present\\:\\ 0\\.022532735072707245\ \(0\)\
\-\ demonstrates\\:\\ 0\\.022060971657876783\ \(0\)\
\-\ large\\:\\ 0\\.02200215198496597\ \(0\)\
\-\ have\\:\\ 0\\.021936512662442672\ \(0\)\
\-\ surgical\\:\\ 0\\.02134272280581902\ \(0\)\
\-\ after\\:\\ 0\\.021302489331450312\ \(0\)\
\-\ treatment\\:\\ 0\\.020917672877820835\ \(0\)\
\-\ has\\:\\ 0\\.020057776991463536\ \(0\)\
\-\ by\\:\\ 0\\.018647633003193366\ \(0\)\
\-\ disease\\:\\ 0\\.018432748047767875\ \(0\)\
\-\ an\\:\\ 0\\.016791847343111618\ \(0\)\
\-\ was\\:\\ 0\\.015303808621737126\ \(0\)\
\-\ this\\:\\ 0\\.015088995275162194\ \(0\)\
\-\ left\\:\\ 0\\.014979381905783459\ \(0\)\
\-\ patient\\:\\ 0\\.01428240824562989\ \(0\)\
\-\ year\\:\\ 0\\.013532850873651215\ \(0\)\
\-\ old\\:\\ 0\\.01299622135128864\ \(0\)\
